7 results on '"Kanematsu-Yamaki Y"'
Search Results
2. Antiobesity and emetic effects of a short-length peptide YY analog and its PEGylated and alkylated derivatives.
- Author
-
Niida A, Kanematsu-Yamaki Y, Asakawa T, Ishimura Y, Fujita H, Matsumiya K, Nishizawa N, Adachi Y, Mochida T, Tsuchimori K, Yoneyama-Hirozane M, Sakamoto J, Hirabayashi H, Fukui H, Takekawa S, and Asami T
- Subjects
- Alkylation, Amino Acid Sequence, Animals, Anti-Obesity Agents pharmacokinetics, Anti-Obesity Agents therapeutic use, Dogs, Emetics chemistry, Emetics therapeutic use, Emetics toxicity, Half-Life, Infusions, Subcutaneous, Mice, Mice, Inbred C57BL, Mice, Obese, Obesity pathology, Peptide YY pharmacokinetics, Peptide YY therapeutic use, Receptors, Neuropeptide Y agonists, Receptors, Neuropeptide Y metabolism, Vomiting etiology, Anti-Obesity Agents chemistry, Obesity drug therapy, Peptide YY chemistry, Polyethylene Glycols chemistry
- Abstract
Neuropeptide Y2 receptor (Y2R) agonism is an important anorectic signal and a target of antiobesity drug discovery. Recently, we synthesized a short-length Y2R agonist, PYY-1119 (4-imidazolecarbonyl-[d-Hyp
24 ,Iva25 ,Pya(4)26 ,Cha27,36 ,γMeLeu28 ,Lys30 ,Aib31 ]PYY(23-36), 1) as an antiobesity drug candidate. Compound 1 induced marked body weight loss in diet-induced obese (DIO) mice; however, 1 also induced severe vomiting in dogs at a lower dose than the minimum effective dose administered to DIO mice. The rapid absorption of 1 after subcutaneous administration caused the severe vomiting. Polyethylene glycol (PEG)- and alkyl-modified derivatives of 1 were synthesized to develop Y2R agonists with improved pharmacokinetic profiles, i.e., lower maximum plasma concentration (Cmax ) and longer time at maximum concentration (Tmax ). Compounds 5 and 10, modified with 20 kDa PEG at the N-terminus and eicosanedioic acid at the Lys30 side chain of 1, respectively, showed high Y2R binding affinity and induced significant body weight reduction upon once-daily administration to DIO mice. Compounds 5 and 10, with their relatively low Cmax and long Tmax , partially attenuated emesis in dogs compared with 1. These results indicate that optimization of pharmacokinetic properties of Y2R agonists is an effective strategy to alleviate emesis induced by Y2R agonism., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
3. Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.
- Author
-
Nagai H, Kaisho T, Yokoyama K, Asakawa T, Fujita H, Matsumiya K, Noguchi J, Tsuchimori K, Nishizawa N, Kanematsu-Yamaki Y, Dote K, Inooka H, Sakamoto JI, Ohtaki T, Asami T, and Takekawa S
- Subjects
- Animals, Arcuate Nucleus of Hypothalamus physiology, Brain metabolism, Male, Mice, Paraventricular Hypothalamic Nucleus physiology, Proto-Oncogene Proteins c-fos metabolism, Diabetes Mellitus, Experimental drug therapy, Obesity drug therapy, Oligopeptides adverse effects, Oligopeptides therapeutic use, Receptors, Neurotransmitter agonists
- Abstract
Background and Purpose: Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effects, the receptor agonist with the most appropriate profiles for treating obesity and diabetes in terms of efficacy and safety is as yet unknown. Thus, we developed and evaluated novel NMU1/2 receptor-selective agonists., Experimental Approach: Efficacy and safety were assessed in mice with diet-induced obesity (DIO) and those with leptin-deficient diabetes (ob/ob) through repeated peripheral administration of selective agonists to NMU1 (NMU-6102) and NMU2 (NMU-2084), along with non-selective NMU1/2 agonists (NMU-0002 and NMU-6014). We also performed immunohistochemistry for c-Fos protein expression in the brain to probe their mechanisms of action., Key Results: Although both non-selective NMU1/2 agonists and the NMU2-selective agonist had high efficacy compared with the NMU1-selective agonist, only the NMU2-selective agonist led to relatively low adverse effects, such as diarrhoea, in DIO mice. However, the non-selective NMU1/2 agonist and the NMU1-selective agonist, but not the NMU2-selective agonist, were effective in diabetic ob/ob mice. Mechanistically, NMU2-selective agonists preferentially activate pro-opiomelanocortin neurons in the hypothalamic arcuate nucleus but not in the paraventricular nucleus., Conclusions and Implications: These results suggest that an NMU2 receptor-selective agonist may be a well-balanced drug for the treatment of obesity and that an NMU1 receptor-selective agonist may also be beneficial for treating obesity and diabetes once its side effects are minimized., (© 2017 The British Pharmacological Society.)
- Published
- 2018
- Full Text
- View/download PDF
4. A potent neuromedin U receptor 2-selective alkylated peptide.
- Author
-
Nishizawa N, Kanematsu-Yamaki Y, Funata M, Nagai H, Shimizu A, Fujita H, Sakamoto J, Takekawa S, and Asami T
- Subjects
- Alkylation, Amino Acid Sequence, Animals, Appetite Depressants chemistry, Appetite Depressants pharmacology, Eating drug effects, Humans, Male, Mice, Mice, Inbred C57BL, Peptides agonists, Receptors, Neurotransmitter antagonists & inhibitors, Structure-Activity Relationship, Appetite Depressants metabolism, Peptides metabolism, Receptors, Neurotransmitter metabolism
- Abstract
Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both receptors, it is metabolically unstable. Therefore, NMU-8 analogs modified with long-chain alkyl moieties via a linker were synthesized. An octadecanoyl analog (17) with amino acid substitutions [αMePhe
19 , Nle21 , and Arg(Me)24 ] and a linker [Tra-γGlu-PEG(2)] dramatically increased NMUR2 selectivity, with retention of high agonist activity. Subcutaneous administration of 17 induced anorectic activity in C57BL/6J mice. Owing to its high metabolic stability, 17 would be useful in clarifying the physiological role and therapeutic application of NMU., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
5. Highly potent antiobesity effect of a short-length peptide YY analog in mice.
- Author
-
Nishizawa N, Niida A, Adachi Y, Kanematsu-Yamaki Y, Masuda Y, Kumano S, Yokoyama K, Noguchi Y, Asakawa T, Hirabayashi H, Amano N, Takekawa S, Ohtaki T, and Asami T
- Subjects
- Amino Acid Sequence, Animals, Anti-Obesity Agents chemistry, Anti-Obesity Agents pharmacology, Diet, Inhibitory Concentration 50, Male, Mice, Mice, Knockout, Molecular Structure, Peptide YY agonists, Body Weight drug effects, Peptide YY chemistry, Peptide YY pharmacology
- Abstract
Continuous administration of a 14-amino acid peptide YY (PYY) analog, Ac-[d-Pro
24 ,Pya(4)26 ,Cha27,36 ,Aib28,31 ,Lys30 ]PYY(23-36) (4), which has a high binding affinity and agonist activity for the neuropeptide Y2 receptor (Y2R), has previously shown an antiobesity effect in a 2-week diet-induced obesity (DIO) study in mice. However, there remained a possibility to obtain more potent analogs by further improving its pharmacokinetic profile. A combination of the N-terminal 4-imidazolecarbonyl moiety and three amino acid substitutions, trans-4-hydroxy-d-proline (d-Hyp)24 , isovaline (Iva)25 , and γ-methylleucine (γMeLeu)28 , not only improved the binding affinity of the peptide for Y2R but also increased its anorectic activity in lean mice. In a 2-week DIO study in mice, continuous administration of 4-imidazolecarbonyl-[d-Hyp24 ,Iva25 ,Pya(4)26 ,Cha27,36 ,γMeLeu28 ,Lys30 ,Aib31 ]PYY(23-36) (31, PYY-1119) at a dose of 0.03mg/kg/day showed a highly potent antiobesity effect, with more than 10% body weight reduction., (Copyright © 2017 Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
6. Potent Body Weight-Lowering Effect of a Neuromedin U Receptor 2-selective PEGylated Peptide.
- Author
-
Kanematsu-Yamaki Y, Nishizawa N, Kaisho T, Nagai H, Mochida T, Asakawa T, Inooka H, Dote K, Fujita H, Matsumiya K, Hirabayashi H, Sakamoto J, Ohtaki T, Takekawa S, and Asami T
- Subjects
- Animals, Anti-Obesity Agents pharmacokinetics, Anti-Obesity Agents pharmacology, Body Weight drug effects, Dietary Fats administration & dosage, Male, Mice, Inbred C57BL, Naphthalenes chemical synthesis, Naphthalenes pharmacokinetics, Naphthalenes pharmacology, Obesity physiopathology, Peptide Fragments pharmacokinetics, Peptide Fragments pharmacology, Piperazines chemical synthesis, Piperazines pharmacokinetics, Piperazines pharmacology, Structure-Activity Relationship, Anti-Obesity Agents chemical synthesis, Neuropeptides chemistry, Obesity drug therapy, Peptide Fragments chemical synthesis, Polyethylene Glycols chemistry, Receptors, Neurotransmitter agonists
- Abstract
Neuromedin U (NMU) is a neuropeptide that mediates a variety of physiological functions via its receptors, NMUR1 and NMUR2. Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity. A short form of NMU (NMU-8) has potent agonist activity for both receptors but is metabolically unstable. Therefore, we designed and synthesized NMU-8 analogues modified by polyethylene glycol (PEG; molecular weight, 20 kDa; PEG20k) via a linker. 3-(2-Naphthyl)alanine substitution at position 19 increased NMUR2 selectivity of NMU-8 analogues with retention of high agonist activity. Compound 37, an NMUR2-selective PEG20k analogue containing piperazin-1-ylacetyl linker, exhibited a potent body weight-lowering effect with concomitant inhibition of food intake in a dose-dependent manner (body weight loss of 12.4% at 30 nmol/kg) by once-daily repeated dosing for 2 weeks in mice with diet-induced obesity.
- Published
- 2017
- Full Text
- View/download PDF
7. Identification of ligand-selective peptidic ActRIIB-antagonists using phage display technology.
- Author
-
Sakamoto K, Kanematsu-Yamaki Y, Kamada Y, Oka M, Ohnishi T, Miwa M, Asami T, and Inooka H
- Abstract
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its various physiological activities, ActRIIB interacts with activin and multiple other ligands including myostatin (MSTN), growth differentiation factor 11 (GDF11), and bone morphogenetic protein 9 (BMP9). Notably, the protein-protein interaction (PPI) between ActRIIB and MSTN negatively controls muscular development. Therefore, this PPI has been targeted for effective treatment of muscle degenerative diseases such as muscular dystrophy and sarcopenia. Here, we report the identification of ligand-selective peptidic ActRIIB-antagonists by phage display technology. Our peptides bound to the extracellular domain of ActRIIB, inhibited PPIs between ActRIIB expressed on the cell surface and its ligands, and subsequently suppressed activation of Smad that serves as the downstream signal of the ActRIIB pathway. Interestingly, these peptidic antagonists displayed different ligand selectivities; the AR2mini peptide inhibited multiple ligands (activin A, MSTN, GDF11, and BMP9), AR9 inhibited MSTN and GDF11, while AR8 selectively inhibited MSTN. This is the first report of artificial peptidic ActRIIB-antagonists possessing ligand-selectivity.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.